0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-09-01 Sage Accounts Production Advanced 2024 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP SC699440 2023-09-01 2024-08-31 SC699440 2024-08-31 SC699440 2023-08-31 SC699440 2022-09-01 2023-08-31 SC699440 2023-08-31 SC699440 2022-08-31 SC699440 bus:LeadAgentIfApplicable 2023-09-01 2024-08-31 SC699440 bus:Director1 2023-09-01 2024-08-31 SC699440 core:WithinOneYear 2024-08-31 SC699440 core:WithinOneYear 2023-08-31 SC699440 core:ShareCapital 2024-08-31 SC699440 core:ShareCapital 2023-08-31 SC699440 core:RevaluationReserve 2024-08-31 SC699440 core:RetainedEarningsAccumulatedLosses 2024-08-31 SC699440 core:RetainedEarningsAccumulatedLosses 2023-08-31 SC699440 core:CostValuation core:Non-currentFinancialInstruments 2023-08-31 SC699440 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-08-31 SC699440 core:DisposalsRepaymentsInvestments core:Non-currentFinancialInstruments 2024-08-31 SC699440 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2024-08-31 SC699440 core:CostValuation core:Non-currentFinancialInstruments 2024-08-31 SC699440 core:Non-currentFinancialInstruments 2024-08-31 SC699440 core:Non-currentFinancialInstruments 2023-08-31 SC699440 bus:SmallEntities 2023-09-01 2024-08-31 SC699440 bus:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 SC699440 bus:SmallCompaniesRegimeForAccounts 2023-09-01 2024-08-31 SC699440 bus:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 SC699440 bus:FullAccounts 2023-09-01 2024-08-31
COMPANY REGISTRATION NUMBER: SC699440
EMOD Investments Limited
Filleted Unaudited Financial Statements
31 August 2024
EMOD Investments Limited
Financial Statements
Year ended 31 August 2024
Contents
Page
Report to the board of directors on the preparation of the unaudited statutory financial statements
1
Statement of financial position
2
Notes to the financial statements
3
EMOD Investments Limited
Report to the Board of Directors on the Preparation of the Unaudited Statutory Financial Statements of EMOD Investments Limited
Year ended 31 August 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of EMOD Investments Limited for the year ended 31 August 2024, which comprise the statement of financial position and the related notes from the company's accounting records and from information and explanations you have given us. As a practising member firm of ICAS, we are subject to its ethical and other professional requirements which are detailed at www.icas.com/accountspreparationguidance. This report is made solely to the Board of Directors of EMOD Investments Limited, as a body. Our work has been undertaken solely to prepare for your approval the financial statements of EMOD Investments Limited and state those matters that we have agreed to state to you, as a body, in this report in accordance with the requirements of ICAS as detailed at www.icas.com/accountspreparationguidance. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than EMOD Investments Limited and its Board of Directors, as a body, for our work or for this report.
It is your duty to ensure that EMOD Investments Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of EMOD Investments Limited. You consider that EMOD Investments Limited is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the financial statements of EMOD Investments Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
GILLILAND & COMPANY Chartered accountants
216 West George Street Glasgow G2 2PQ
27 August 2025
EMOD Investments Limited
Statement of Financial Position
31 August 2024
2024
2023
Note
£
£
£
Fixed assets
Investments
4
1,128,200
889,133
Current assets
Cash at bank and in hand
4,664
Creditors: amounts falling due within one year
5
214,341
364,520
---------
---------
Net current liabilities
209,677
364,520
------------
---------
Total assets less current liabilities
918,523
524,613
Provisions
Taxation including deferred tax
11,832
---------
---------
Net assets
906,691
524,613
---------
---------
Capital and reserves
Called up share capital
100
100
Revaluation reserve
59,408
Profit and loss account
847,183
524,513
---------
---------
Shareholders funds
906,691
524,613
---------
---------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 27 August 2025 , and are signed on behalf of the board by:
Mr G McGowan
Director
Company registration number: SC699440
EMOD Investments Limited
Notes to the Financial Statements
Year ended 31 August 2024
1. General information
The company is a private company limited by shares, registered in Scotland. The address of the registered office is 216 West George Street, Glasgow, G2 2PQ, Scotland.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and hat are readily convertible to known amounts of cash with insignificant risk of change in value.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Investments
Shares in group undertakings
Other investments other than loans
Total
£
£
£
Cost
At 1 September 2023
100
889,033
889,133
Additions
457,765
457,765
Disposals
( 288,098)
( 288,098)
Revaluations
69,400
69,400
----
------------
------------
At 31 August 2024
100
1,128,100
1,128,200
----
------------
------------
Impairment
At 1 September 2023 and 31 August 2024
----
------------
------------
Carrying amount
At 31 August 2024
100
1,128,100
1,128,200
----
------------
------------
At 31 August 2023
100
889,033
889,133
----
------------
------------
The company holds the entire share capital of Gerard McGowan Ophthalmic Consultants Ltd.
5. Creditors: amounts falling due within one year
2024
2023
£
£
Amounts owed to group undertakings and undertakings in which the company has a participating interest
214,341
364,520
---------
---------
6. Related party transactions
During the period the company received funds from its subsidiary Gerard McGowan Opthalmic Consultants Ltd, as at 31st August 2024 the company owed £214,341.(2023: £364,250)
7. Controlling party
The company is under the control of the directors throughout the current period.